SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-06-26
👔
ARS Pharmaceuticals, Inc.
@SPRY_InsiderForm 4 Filing: RA Capital Nexus Fund II, L.P. Acquires (Grant) shares of $SPRY
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
ARS Pharmaceuticals, Inc.
Ticker: $SPRY
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-06-24
Shares: 30,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, RA Capital Nexus Fund II, L.P., holds the title of Director at ARS Pharmaceuticals, Inc..
On 2026-06-24, the insider transacted 30,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
RA Capital Nexus Fund II, L.P. (Director) was granted $0 of $SPRY
Post-Transaction Position: 30,000 shares
SEC Accession No: 0001231919-26-000704 (CIK: 1825376)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.